Contents

BioBoard
•  Rockeby Biomed Cancel Agreement to Supply Test Kits to Turkish Poultry Industry
•  India Launches Healthcare Drive
•  Japan's Eisai Company Says 11 Die in Alzheimer's Drug Trial
•  Innovation Dynamics to Set up Office in Perth
•  Millipore India Sets up EOU to Manufacture Purification Systems for Global Markets
•  Life Therapeutics to Spin Out Two Divisions into a New Company
•  GSK to Build Vaccine Facility in Taiwan
•  H5N1 Bird Flu has Evolved into Two Strains
•  Biocon to be Investigated for Drug Violations

Special Feature
•  Biometrics and E-Authentication Biometrics for Inanimate Objects: The Emergence of Commercially Viable 'Materiametrics'

Industry Watch
•  Australian Drug Discovery Company, Incitive Ltd, Announces Initial Public Offer
•  Biosignal Collaborates with Ciba Specialty Chemicals
•  Brisbane's Tissue Therapy Partners Canada's QSV Biologics
•  Cellestis Signs Agreements on TB and Cytomegalovirus with FIND
•  Mesoblast Obtained an Exclusive Worldwide License to Commercialize New Drug-eluting Stent Technology
•  Narhex Life Sciences Ltd: An Emerging Australian Biotechnology Company
•  Norwood Immunology Collaborates with Australian Stem Cell Center and Monash University
•  Premier Bionics' Subsidiary Medic Vision Team up with the University of Melbourne and the CSIRO
•  PharmaEng signs LOI to Purchase Beijing Lixin PharmaTech
•  Japan's Bioventures Today -- Noas Medical Co Ltd

Research Findings
•  Singapore Heart, Stroke and Cancer Center Conducts Research on CT Coronary Angiogram

Rules & Regulations
•  Singapore's TCM Practitioner Board Sets up New Guidelines on Ethical Conduct

General News
•  TNT Opens Dedicated National Life Science Distribution Center in Shanghai

Commentaries/Analyses
•  Commercializing Regenerative Medicine Technologies: Achieving Scale in China

Conference Calendar